Exhibit 10.1

                                  30 April 2010



                              Enox Biopharma, Inc.



                                Dr. Lundberg Jon



                               Dr. Weitzberg Eddie



                                  Nitricare HB



                  Assignment of Patents and Patent Applications
<PAGE>
                              DATED APRIL 29, 2010

BETWEEN:

(1)      ENOX  BIOPHARMA,  INC., a company  incorporated in the state of Nevada,
         USA, whose principal  office is at 3849 West 13th Avenue,  Vancouver BC
         V6R239, Canada (the "ASSIGNEE");

(2)      DR. LUNDBERG JON,  Swedish Passport number 45618433 whose address is at
         Stenbocksvagen 6, S-182 62, Djursholm, Stockholm, Sweden ("LUNDBERG");

(3)      DR. WEITZBERG EDDIE,  Swedish Passport number 56589903 whose address is
         at Nybrogtan 24, S-114 39 Stockholm, Sweden ("WEITZBERG"),

(4)      NITRICARE HB, a [company]  incorporated under the laws of Sweden, whose
         a  registered  address is at  Stenbocksvagen  6,  S-182 62,  Djursholm,
         Stockholm,  Sweden (the  "NITRICARE"  and  together  with  Lundberg and
         Weitzberg - the "ASSIGNOR")

(together, the "PARTIES").

(A)      WHEREAS Lundberg and Weitzberg are the sole inventors of the Inventions
         (as defined below).

(B)      AND WHEREAS Nitricare is wholly owned (100%) by Lundberg and Weitzberg.

(C)      AND WHEREAS the Assignor is the  proprietor of the  Inventions  and the
         applicant for the Patents (as defined below).

(D)      AND WHEREAS the Assignee is interested in receiving and being  assigned
         and the  Assignor  has agreed to assign and transfer the Patents to the
         Assignee on the terms set out in this Agreement.

IT IS THEREBY AGREED:

1.       INTERPRETATION

1.1      In this Agreement the following words and expressions shall, unless the
         context otherwise requires, have the following meanings:

         "BUSINESS  DAY": a day other than a Saturday,  Sunday or public holiday
         when banks are normally open for business.

         "IMPROVEMENT":  any  improvement,  enhancement or  modification  to the
         technology  that  is  the  subject  of any  of  the  Patents  or to any
         Invention.

         "INVENTION":  any  invention  method  or device  described,  disclosed,
         contained and claimed in any Patent.

         "PATENT":  any patent applications,  short particulars of which are set
         out in  SCHEDULE  1, any similar  application  filed in any  additional
         country or  territory  in the world,  and any patent  issued in respect
         thereto.

1.2      Clause and schedule  headings  shall not affect the  interpretation  of
         this Agreement.

1.3      The schedules  form part of this  Agreement and shall have effect as if
         set out in full in the body of this Agreement.

1.4      Unless the context  otherwise  requires,  words in the singular include
         the plural and in the plural include the singular.

1.5      Any words following the terms INCLUDING,  INCLUDE, IN PARTICULAR or any
         similar  expression  shall be construed as  illustrative  and shall not
         limit the sense of the words preceding those terms.

1.6      A PERSON includes a natural person,  corporate or  unincorporated  body
         (whether or not having separate legal personality).

                                        2
<PAGE>
1.7      Any  obligation  in this  Agreement  on a  person  not to do  something
         includes, without limitation, an obligation not to agree, allow, permit
         or acquiesce in that thing being done.

1.8      Any  obligation,   warranty  and  representation  of  the  Assignor  is
         collectively and severally an obligation,  warranty and  representation
         of Lundberg and Weitzberg and Nitricare.

2.       ASSIGNMENT

         Pursuant to and for the  consideration  set out in Clause 4 below,  the
         Assignor   hereby  vests,   transfers  and  assigns  to  the  Assignee,
         absolutely with full title guarantee,  all its right, title,  interest,
         claim  and  demand  in and to  all  and  any  Patents  and  Inventions,
         including:

2.1      in respect of any and each application in the Patents:

          (a)  the right to claim  priority  from and to  prosecute  and  obtain
               grant of patent; and

          (b)  the right to file  divisional  applications  based thereon and to
               prosecute  and  obtain  grant  of  patent  on each  and any  such
               divisional application;

2.2      in respect of each and any Invention, the right to file an application,
         claim priority from such application, and prosecute and obtain grant of
         patent  or  similar  protection  in or in  respect  of any  country  or
         territory in the world;

2.3      the right to extend to or  register  in or in respect of any country or
         territory in the world each and any of the Patents  (including each and
         any  of  the  applications  comprised  in  the  Patents)  or  filed  as
         aforesaid,  and to extend to or  register  in, or in  respect  of,  any
         country or territory in the world any patent or like protection granted
         on any of such applications.

2.4      the absolute  entitlement to any patents granted pursuant to any of the
         applications comprised in the Patents or filed as aforesaid; and

2.5      the right to bring, make, oppose, defend, appeal proceedings, claims or
         actions  and obtain  relief (and to retain any  damages  recovered)  in
         respect of any infringement,  or any other cause of action arising from
         ownership,  of any of the Patents or any patents  granted on any of the
         applications  in the Patents or filed as aforesaid,  whether  occurring
         before, on or after the date of this assignment.

3.       IMPROVEMENTS

3.1      If the Assignor makes,  devises,  or discovers,  or otherwise  acquires
         rights in, any  Improvement it shall,  promptly  notify the Assignee in
         writing, giving details of the Improvement.

3.2      Unless prohibited by law, the Assignor shall immediately  assign,  vest
         and transfer to the Assignee, for no additional consideration, all such
         Improvements  and the  Inventions  related  thereto which shall be then
         regarded as part of the Patents,  and the  provision  of the  Agreement
         shall  apply  to  them  (subject  to the  applicable  changes).  If any
         applicable   law   prohibits   such   assignment   for  no   additional
         consideration,   the   Parties   hereby   agree  that  the   additional
         consideration  to be paid for the assignment of  Improvements  shall be
         ONE US Dollar.

         Notwithstanding  the above,  if by the operation of law such assignment
         is  not  possible,  the  Assignor  shall  grant  the  Assignee,  for no
         additional  consideration,  a  worldwide,  royalty-free,   irrevocable,
         perpetual exclusive licence to use, make, manufacture, sell, reproduce,
         distribute,  modify,  display,  prepare  derivative works, or any other
         rights available with respect to Improvements and any rights therein.

4.       CONSIDERATION

         In  consideration  for the  assignment  and  transfer  of the  Patents,
         Inventions and Improvements  hereunder,  Nitricare HB shall receive the
         following compensation:

4.1      Fifteen  thousands US dollars  (USD 15,000) upon the  execution of this
         Agreement, the receipt of which the Assignor expressly acknowledges;

                                        3
<PAGE>
4.2      Forty-Five thousands US dollars (USD 45,000), to be paid in three equal
         quarterly  instalments  of fifteen  thousands  US dollars  (USD 15,000)
         each, on the following dates: July 30th, 2010,  October 29th, 2010, and
         January 31st 2011.

4.3      A warrant [, issued upon execution of this  Agreement,] to purchase two
         hundred thousand (200,000) shares of common stock,  $0.0001,  par value
         per share,  of the  Assignee,  at an exercise  price and subject to the
         terms set out in the  warrant,  a form of which is  attached  hereto as
         SCHEDULE 2.

4.4      It is hereby clarified and agreed that the said  consideration is final
         and conclusive, and that the Assignor (or any of Lundberg and Weitzberg
         and  Nitricare)  or any  third  party,  shall  not be  entitled  to any
         additional  consideration,  payment,  fee  or  royalties  of  any  kind
         whatsoever,  even if the Assignee generates or receives any revenues or
         payments of any type in connection with the Patents.

4.5      Each Party shall be  responsible  for its own tax  liabilities  arising
         from this Agreement.  However,  if the Assignor is required to withhold
         any amounts from any  payment,  it shall  effect such  withholding  and
         remit such amounts to the appropriate taxing authorities.

         For the  avoidance of doubt it is clarified  that all payments  made by
         the Assignee under this agreement are inclusive of VAT, if applicable.

5.       REPRESENTATIONS AND WARRANTIES

5.1      Each Party hereby represents and warrants to the other Parties that:

          (a)  Assignee has the requisite corporate power and authority to enter
               into  and  perform  this  Agreement  and  issue  the  Warrant  in
               accordance  with the terms hereof.  The  execution,  delivery and
               performance   of  this   Agreement   by  the   Assignee  and  the
               consummation by it of the transactions  contemplated  hereby have
               been  duly and  validly  authorized  by all  necessary  corporate
               action,  and no further consent or  authorization  of Assignee or
               its Board of Directors or stockholders is required;

          (b)  It will not breach the terms of any agreement or arrangement with
               any third party by entering into this  Agreement  and  performing
               its obligations hereunder;

          (c)  Its obligations under this Agreement  constitute its legal, valid
               and binding  obligations,  enforceable  in accordance  with their
               respective    terms    subject    to    applicable    bankruptcy,
               reorganisation,  insolvency, moratorium or similar laws affecting
               creditors'  rights  generally  and  to  equitable  principles  of
               general application; and

          (d)  No litigation,  arbitration or administrative  suit or proceeding
               before any court, tribunal,  governmental body, agency,  official
               or  arbitrator  is pending or, so far as it is aware,  threatened
               against it hat would, if adversely determined, affect its ability
               to  perform  its  obligations  under this  Agreement,  or that is
               likely to affect the legality, validity or enforceability against
               it of the  Agreement  or its ability to perform  its  obligations
               under this Agreement.

5.2      In  addition,  the  Assignor  hereby  represents  and  warrants  to the
         Assignee that:

          (a)  Lundberg and Weitzberg are the sole  inventors and  developers of
               the   Inventions,    without   any   contribution,    assistance,
               participation or alleged rights of any third party;

          (b)  it is the sole legal and  beneficial  owner of the Inventions and
               the  Patents  and it is  properly  registered  as  the  inventor,
               applicant  and  proprietor  thereof  and no other  person has any
               rights in or with respect to any Patent;

          (c)  it is entitled to transfer,  vest and assign the  Inventions  and
               Patents in accordance with the terms of this Agreement;

          (d)  all declarations and documents  required,  until the date of this
               Agreement,  by the various  patent  offices in the  countries  in
               which  the  Patents  are  registered,  in order to  register  the
               Patents  have  been  duly  executed,   submitted,   approved  and
               registered;

                                        4
<PAGE>
          (e)  all application,  registration and renewal fees until the date of
               this Agreement in respect of each of the Patents have been paid;

          (f)  it has not transferred, vested, assigned or licensed or otherwise
               granted any of the rights under the Patents;

          (g)  each  Patent is free  from any  encumbrance,  security  interest,
               option,  mortgage,  charge,  lien,  right of third party or other
               adverse rights;

          (h)  it is unaware of any  infringement or likely  infringement of, or
               any challenge or likely  challenge to the validity of, any of the
               Patents  or of  anything  that might  render  any of the  Patents
               invalid or subject to a compulsory  licence  order or prevent any
               application in the Patents proceeding to grant;

          (i)  the  exploitation  of the Patents will not infringe the rights of
               any third party; and

          (j)  all  previous  assignments  of the  Patents  are  valid  and were
               registered within applicable time limits

6.       INDEMNITY

6.1      The Assignor shall indemnify and hold the Assignee harmless against all
         and any loss, damages,  liability and costs (including reasonable legal
         expenses)  that the  Assignee  suffers  or  incurs as a result of or in
         connection  with any breach by the Assignor of the warranties in Clause
         5 above or other  obligations  under this Agreement.  At the request of
         the  Assignee  and at its  expense,  the  Assignor  shall  provide  all
         reasonable  assistance  to enable  the  Assignee  to resist  any claim,
         action or proceedings  brought against the Assignee as a consequence of
         that breach. This indemnity shall apply whether or not the Assignee has
         been negligent or at fault.

6.2      If a payment due from the Assignor  under this clause is subject to tax
         (whether by way of direct assessment or withholding at its source), the
         Assignee shall be entitled to receive from the Assignor such amounts as
         shall  ensure  that the net  receipt,  after tax,  to the  Assignee  in
         respect  of the  payment  is the same as it would  have  been  were the
         payment not subject to tax.

6.3      Nothing  in this  Agreement  shall  have the  effect  of  excluding  or
         limiting  any  liability  for  death  or  personal   injury  caused  by
         negligence or for fraud.

7.       FURTHER ASSURANCES

7.1      The Assignor shall, at the Assignee's expense,  perform (or procure the
         performance  of) all  further  acts and things,  and sign,  execute and
         deliver (or procure the signing,  execution or delivery of) all further
         deeds,  declarations and documents,  required by various patent offices
         in  the  countries  in  which  the  Patents  are  registered  or may be
         registered,  or by any law, or which the Assignee requests, in order to
         vest in the Assignee the full benefit of the right,  title and interest
         assigned to the Assignee under this Agreement,  and to ensure that such
         assignments   have  been  duly   executed,   submitted,   approved  and
         registered, including but not limited to:

          (a)  registration  of the Assignee as applicant for, or proprietor of,
               the Patents;

          (b)  application for any patent with respect to the Inventions, in any
               territory or Country in the world;

          (c)  assisting the Assignee in obtaining,  maintaining,  defending and
               enforcing any Patent,  and assisting  with any other  proceedings
               which may be brought by or against the Assignee against or by any
               third party  relating to the rights  assigned by this  Agreement;
               and

          (d)  at the request and expense of the Assignee provide any assistance
               required in connection with any other  proceedings  regarding any
               of the Patents.

7.2      The  Assignor  shall  otherwise  do  all  it  reasonably  can,  at  the
         Assignee's  expense, to vest the rights and title to the Patents in the
         Assignee.

                                        5
<PAGE>
7.3      The Assignor hereby appoints the Assignee to be its attorney to execute
         and do any such instrument or thing, and generally to use its name, for
         the purpose of giving the Assignee the benefit of this  Agreement.  The
         Assignor  acknowledges in favour of a third party that a certificate in
         writing  signed by the Assignee or any person  appointed in  accordance
         with Clause 7.5 that any  instrument  or act falls within the authority
         conferred by this Agreement  shall be conclusive  evidence that such is
         the case.

7.4      This  power  of  attorney  is  irrevocable  as long  as the  Assignor's
         obligations under this agreement remain undischarged.

7.5      Without prejudice to Clause 7.2, the attorney may, in any way it thinks
         fit and in the name and on behalf of the Assignor:

          (a)  take any action  that this  Agreement  requires  the  Assignor to
               take;

          (b)  exercise any rights which this  Agreement  gives to the Assignor;
               and

          (c)  appoint  and remove one or more  substitute  attorneys  with full
               power  as the  Assignor's  attorney  on terms  that the  attorney
               thinks fit.

7.6      The Assignor must ratify and confirm  everything  that the attorney and
         any substitute attorney does or arranges using the powers granted under
         this clause.

7.7      The Assignor  shall  without  delay  communicate  and deliver up to the
         Assignee  all  available  information  and  materials  relating  to all
         Inventions, Patents and Improvements.

7.8      The Assignor  shall give notice in writing to the Assignee  promptly on
         becoming aware of any  infringement  or suspected  infringement  of any
         Patent.

7.9      The Assignor  shall not do or allow to be done anything  which would or
         might prejudice the rights of the Assignee under this Agreement.

8.       PATENTS RELATED COSTS

         For the avoidance of doubt it is hereby  clarified and agreed that from
         the date of this Agreement and thereafter, the Assignee will assume all
         costs and expenses  related to the Patents (other than those explicitly
         set out under Clause 5.2(e)), including their maintenance costs and all
         costs associated with their approval.

9.       RE-ASSIGNMENT

9.1      Notwithstanding  anything to the contrary under this  Agreement,  it is
         agreed that if, at any time prior to the execution of the Warrant,  the
         Assignee:  (i) ceases to do business;  (ii)  becomes  unable to pay its
         debts as they fall due; (iii) becomes or is deemed insolvent;  (iv) has
         a  receiver,  liquidator,  manager,  administrator  or similar  officer
         appointed in respect of the whole or any part of its assets or business
         (or is the  subject of a filing with any court for the  appointment  of
         any such officer);  (v) makes any  composition or arrangement  with its
         creditors;  or (vi) any  equivalent or similar  action or proceeding is
         taken or suffered in any jurisdiction, and the same is not dismissed or
         discharged within 30 days, the Assignor may demand, by a written notice
         to the Assignee,  to revoke the  assignment and transfer of the Patents
         and Inventions taken in accordance with this Agreement, as follows:

          (a)  the Assignee shall vest, transfer and assign back to the Assignor
               all the rights,  titles and  interests  in and to the Patents and
               Inventions, that were assigned or transferred to it in accordance
               with this Agreement;

          (b)  the Assignor shall return to the Assignee any and all payments it
               has received in accordance with this Agreement,  plus interest at
               a rate of 5% per annum,  compounded  daily,  from the date it has
               received  such payment until the date such payment is returned in
               accordance with this Clause; and

          (c)  the  Assignor  shall  return to the  Assignee  the warrant it has
               received under Clause 4.3.

                                        6
<PAGE>
9.2      the Parties shall,  at the Assignor  expense,  perform all further acts
         and  things,  and sign,  execute  and  deliver  of all  further  deeds,
         declarations and documents, as may be required for such re-assignment.

10.      VARIATION

         An amendment or a variation of this Agreement shall be valid only if it
         is made in writing and signed by all Parties.

11.      REMEDIES

11.1     The  failure  to  exercise  or delay in  exercising  a right or  remedy
         provided by this  Agreement  or by law does not  constitute a waiver of
         the right or remedy or a waiver of other rights or remedies.  No single
         or partial  exercise of a right or remedy provided by this Agreement or
         by law prevents further exercise of the right or remedy or the exercise
         of another right or remedy.

11.2     Each  Party's  rights and  remedies  contained  in this  Agreement  are
         cumulative and not exclusive of rights or remedies provided by law.

12.      SEVERABILITY

         If, at any time, any provision of this Agreement is or becomes illegal,
         invalid  or   unenforceable  in  any  respect  under  any  law  of  any
         jurisdiction,  neither the legality,  validity or enforceability of the
         remaining  provisions nor the legality,  validity or  enforceability of
         such  provision  in any  other  respect  or under  the law of any other
         jurisdiction will in any way be affected or impaired.

13.      ENTIRE AGREEMENT

         This  Agreement  constitutes  the entire  agreement  and  understanding
         between the Parties and supersedes all other  agreements  both oral and
         in writing between them in respect to its subject matter.

14.      ASSIGNMENT

         Otherwise as expressly  provided  herein, a Party shall not be entitled
         to assign  any of its  rights  and  obligations  under  this  Agreement
         without the prior written approval of the other Parties.

15.      NO PARTNERSHIP OR AGENCY

         Nothing  in this  Agreement  is  intended  to, or shall be  deemed  to,
         constitute a  partnership  or joint  venture of any kind between any of
         the Parties,  not  constitute  any Party the agent of another party for
         any purpose, nor constitute an  employer-employee  relationship between
         the Parties.

16.      RIGHTS OF THIRD PARTIES

         A person who is not a party to this Agreement shall not have any rights
         under or in connection with it.

17.      NOTICES

         Any notice  required or allowed under this  Agreement  shall be made in
         writing by  registered  mail  return  receipt  requested,  courier,  or
         facsimile  and served to  addresses  mentioned  at the  heading of this
         Agreement,  or to such other  address,  fax  number,  as a Party  shall
         notify  the other  Parties  in  writing  from time to time.  Any notice
         served by post shall be deemed to have been served three  Business Days
         following  the date of  posting;  or the next  Business  Day  following
         transmission by facsimile;  or if delivered personally,  at the time of
         delivery; and in proving such service it shall be sufficient proof that
         the envelope containing the notice was properly addressed and posted as
         a pre-paid letter by registered delivery post.

18.      COUNTERPARTS

         This Agreement may be executed in any number of  counterparts,  each of
         which shall be an original and all of which together shall evidence the
         same agreement.

                                        7
<PAGE>
19.      GOVERNING LAW AND JURISDICTION

19.1     This  Agreement  and  any  disputes  or  claims  arising  out  of or in
         connection  with its subject  matter are  governed by and  construed in
         accordance with the law of Nevada,  USA  (disregarding  any conflict of
         laws rules).

19.2     The  parties  irrevocably  agree that the  courts of Nevada  shall have
         non-exclusive  jurisdiction  to settle any dispute or claim that arises
         out of or in connection  with this  assignment or its subject matter or
         formation (including non-contractual disputes or claims).

IN WITNESS  WHEREOF the parties have executed  this  Agreement on the date first
above written.

NITRICARE HB


By: /s/ Jon Lundberg               /s/ Eddie Weitzberg
   ----------------------------    ----------------------------
Name:  Jon Lundberg                Eddie Weitzberg
Title: Prof.                       Prof.

DR. LUNDBERG JON


/s/ Jon Lundberg
-------------------------------

DR. WEITZBERG EDDIE


/s/ Eddie Weitzberg
-------------------------------

ENOX BIOPHARMA, INC.

By: /s/ Itamar David
   ----------------------------
Name:  Itamar David
Title: CEO


                                       8
<PAGE>
                            SCHEDULE 1 - THE PATENTS

<TABLE>
<CAPTION>
Territory       Publication no     Application no         Date filed    [Date granted]              Title
---------       --------------     --------------         ----------    --------------              -----
<S>             <C>               <C>                    <C>           <C>                 <C>
Israel                                176289              2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

South Africa                          2006/05719          2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

South Korea                           2006-7013479        2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

Norway                                20063105            2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

China                                 200480041720.7      2004-12-15    Issue fee paid     New device and method for
                                                                        March 18, 2010     prevention of nocosomial
                                                                                           infections

Japan           P2007-534361A         2006-545287         2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

EPO                                   04809058.3          2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

Australia                             2004296174          2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

USA             US 2007/0239107       10/583,113          2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections

Hong Kong       HK1103667             07112417.3          2004-12-15                       New device and method for
                                                                                           prevention of nocosomial
                                                                                           infections
</TABLE>

                                        9
<PAGE>
                                   SCHEDULE 2

                                   THE WARRANT

THE WARRANT EVIDENCED HEREBY, AND THE SECURITIES ISSUABLE  HEREUNDER,  HAVE BEEN
AND SHALL BE ISSUED  WITHOUT  REGISTRATION  UNDER THE SECURITIES ACT OF 1933, AS
AMENDED,  OR THE APPLICABLE STATE SECURITY LAWS. THE WARRANT AND SUCH SECURITIES
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE,
AND SHALL NOT BE SOLD, TRANSFERRED,  PLEDGED OR HYPOTHECATED UNLESS THE PROPOSED
DISPOSITION IS THE SUBJECT OF A CURRENTLY EFFECTIVE REGISTRATION STATEMENT UNDER
SAID ACT AND UNDER  APPLICABLE  STATE  SECURITIES LAWS OR UNLESS THE COMPANY HAS
RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO
THE COMPANY, TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED UNDER SAID ACT
AND SUCH STATE SECURITIES LAWS IN CONNECTION WITH SUCH DISPOSITION.

                              ENOX BIOPHARMA, INC.

                          COMMON STOCK PURCHASE WARRANT

                                 Warrant No: W73

                        Original Issue Date: May 3, 2010

                       Void After: 11:59 P.M., May 2, 2012

                           This Warrant is Issued to:

                                  NITRICARE HB

(hereinafter  called the "HOLDER,"  which term shall include the Holder's  legal
representatives,  heirs,  successors  and  assigns)  by Enox  Biopharma,  Inc. a
corporation  (hereinafter  referred to as the  "COMPANY").  This  Warrant may be
transferred by the Holder only in accordance with the provisions of Section 10.

     1.  EXERCISE OF WARRANT.  For value  received  and subject to the terms and
conditions hereinafter set forth, the Holder is entitled, upon surrender of this
Warrant  at any time on or after May 3, 2010 and on or prior to May 2, 2012 (the
"EXERCISE  DATE")  (along  with the  exercise  notice form  annexed  hereto (the
"EXERCISE  NOTICE")  duly  executed,  and any  certificate(s)  representing  the
Warrant Shares (as hereinafter  defined) (the "WARRANT SHARE  CERTIFICATE"))  at
the office of the Company at Suite #303, 1687 West Broadway,  Vancouver, British
Columbia or such other  office in the United  States of which the Company  shall
notify the Holder  hereof in  writing,  to  purchase  from the  Company,  at the
purchase  price  hereinafter  specified  (as  adjusted  from  time to time,  the
"EXERCISE PRICE"), up to 200,000 shares (the "WARRANT SHARES") (as adjusted from
time to time) of the Common Stock, 1.00 par value per share, of the Company (the
"COMMON  STOCK").  The initial  Exercise  Price  shall be $1.00 per share.  This
Warrant may be exercised in whole or in part on an Exercise Date.

     2. ISSUANCE OF WARRANT SHARES.  As promptly as practicable  after surrender
of this Warrant and receipt of payment of the Exercise Price,  the Company shall
issue and deliver to the Holder a certificate  or  certificates  for the Warrant
Shares purchased  hereunder,  in certificates of such  denominations and in such
names as the Holder may specify.

                                       10
<PAGE>
     3. PAYMENT OF EXERCISE  PRICE.  Payment of the Exercise Price shall be made
by check  made  payable  to the  order of the  Company  or by wire  transfer  of
immediately  available  funds to a bank  account  designated  by the Company [in
available funds in U.S. Dollars].

     4.  ADJUSTMENT FOR DIVIDENDS,  DISTRIBUTIONS,  SUBDIVISIONS,  COMBINATIONS,
MERGERS, CONSOLIDATIONS OR SALE OF ASSETS

     4.1 Manner of Adjustment.

     (a)  Stock  Dividends,  Distributions  or  Subdivisions.  In the  event the
Company  shall  issue  shares  of  Common  Stock  in  a  stock  dividend,  stock
distribution or  subdivision,  the Exercise Price in effect  immediately  before
such stock dividend, stock distribution or subdivision shall,  concurrently with
the effectiveness of such stock dividend, stock distribution or subdivision,  be
proportionately  decreased and the number of shares of Common Stock  purchasable
by exercise of this Warrant shall be proportionately increased.

     (b) Combinations or Consolidations.  In the event the outstanding shares of
Common  Stock  shall  be  combined  or  consolidated,   by  reclassification  or
otherwise, into a lesser number of shares of Common Stock, the Exercise Price in
effect   immediately   prior  to  such  combination  or   consolidation   shall,
concurrently  with the  effectiveness of such combination or  consolidation,  be
proportionately  increased and the number of shares of Common Stock  purchasable
by exercise of this Warrant shall be proportionately decreased.

     (c) Adjustment for Reclassification, Exchange or Substitution. In the event
that the class of securities issuable upon the exercise of this Warrant shall be
changed into the same or a different number of shares of any class or classes of
stock, whether by capital  reorganization,  reclassification or otherwise (other
than any event addressed by Sections 4.1(a), 4.1(b) or 4.1(d)), then and in each
such event the Holder shall have the right  thereafter  to exercise this Warrant
for the kind and  amount of shares of stock and other  securities  and  property
receivable  upon such  reorganization,  reclassification,  or other  change,  by
holders  of the  number of shares of the class of  securities  into  which  such
Warrant   might   have  been   exercisable   for   immediately   prior  to  such
reorganization,  reclassification,  or change, all subject to further adjustment
as provided herein.

     (d) Adjustment for Merger,  Consolidation  or Sale of Assets.  In the event
that the Company shall merge or consolidate  with or into another entity or sell
all of its assets, this Warrant shall thereafter be exercisable for the kind and
amount of shares of stock or other  securities  or property to which a holder of
the number of shares of Common Stock of the Company deliverable upon exercise of
this Warrant would have been entitled upon such  consolidation,  merger or sale;
and, in such case,  appropriate  adjustment  (as determined in good faith by the
Company's Board of Directors) shall be made in the application of the provisions
set forth in this Section 4 with  respect to the rights and interest  thereafter
of the Holder of this Warrant,  to the end that the provisions set forth in this
Section 4 shall  thereafter be  applicable,  as nearly as reasonably  may be, in
relation to any shares of stock or other property  thereafter  deliverable  upon
the exercise of this Warrant.

     4.2 Certificate as to  Adjustments.  Upon the occurrence of each adjustment
or readjustment of the Exercise Price pursuant to this Section 4, the Company at
its expense shall promptly compute such adjustment or readjustment in accordance
with the terms hereof and furnish to the Holder a certificate setting forth such
adjustment  or  readjustment  and  showing  in detail  the facts upon which such
adjustment or readjustment is based.

                                       11
<PAGE>
     4.3 Closing of Books. The Company shall at no time close its transfer books
against the transfer of any shares of Common  Stock issued or issuable  upon the
exercise  of this  Warrant in any manner  which  interferes  with the timely and
proper issuance of such shares.

     5.  COVENANTS  OF THE  COMPANY.  During the period  within which the rights
represented  by this Warrant may be  exercised,  the Company  shall at all times
have  authorized  and  reserved  for the  purpose of issue upon  exercise of the
rights  evidenced  hereby,  a  sufficient  number  of  shares  of the  class  of
securities issuable upon exercise of this Warrant to provide for the exercise of
such rights.  All securities which may be issued upon the exercise of the rights
represented by this Warrant shall,  upon issuance,  be duly authorized,  validly
issued, fully paid and non-assessable and free from all taxes, liens and charges
with respect to the issue  thereof.  Upon  surrender for exercise,  this Warrant
shall be canceled and shall not be reissued;  provided,  however,  that upon the
partial exercise hereof a substitute Warrant of like tenor and date representing
the rights to subscribe  for and purchase any such  unexercised  portion  hereof
shall be issued.

     6. NO RIGHTS AS SHAREHOLDER UNTIL EXERCISE.  This Warrant shall not entitle
the  Holder to any voting  rights or any other  rights as a  stockholder  of the
Company but upon  presentation  of this Warrant  with the  Exercise  Notice duly
executed  and the tender of payment of the  Exercise  Price at the office of the
Company  pursuant to the provisions of this Warrant,  the Holder shall forthwith
be deemed a stockholder  of the Company in respect of the  securities  for which
the Holder has so subscribed and paid.

     7. NO  CHANGE  NECESSARY.  The form of this  Warrant  need  not be  changed
because  of any  adjustment  in the  Exercise  Price or in the  number of shares
issuable upon its exercise. A Warrant issued after any adjustment or any partial
exercise or upon replacement may continue to express the same Exercise Price and
the  same  number  of  shares  (appropriately  reduced  in the  case of  partial
exercise) as are stated on this Warrant as initially  issued,  and that Exercise
Price and that number of shares shall be  considered  to have been so changed as
of the close of business on the date of adjustment.

     8.  ADDRESSES  FOR  NOTICES.  All  notices,  requests,  consents  and other
communications hereunder shall be in writing, either delivered in hand or mailed
by registered or certified mail, return receipt requested, or sent by facsimile,
and shall be deemed to have been duly made when delivered:

          If to the Holder, to the Holder's address as shown on the books of the
          Company; or

          If to the Company,  to the address set forth on the first page of this
          Warrant.

     9. SUBSTITUTION.  In the case this Warrant shall be mutilated, lost, stolen
or  destroyed,  the  Company  shall  issue  a new  Warrant  of  like  tenor  and
denomination  and deliver the same (a) in exchange and substitution for and upon
surrender  and  cancellation  of any  mutilated  Warrant,  or (b) in lieu of any
Warrant lost, stolen or destroyed,  upon receipt of evidence satisfactory to the
Company of the loss, theft, or destruction of such Warrant  (including,  without
limitation, a reasonably detailed affidavit with respect to the circumstances of
any  loss,  theft or  destruction),  and of  indemnity  (or,  in the case of the
initial  Holder or any  other  institutional  holder,  an  indemnity  agreement)
satisfactory to the Company.

     10.  TRANSFER  RESTRICTIONS.  This Warrant shall not be transferable by the
Holder and shall be  exercisable  only by the Holder.  Without the prior written
consent  of  the  Company,  the  Warrant  shall  not  be  assigned,  pledged  or
hypothecated in any way (whether by operation of law or otherwise) and shall not
be subject to execution,  attachment or similar process. Any attempted transfer,
assignment,  pledge, hypothecation or other disposition of the Warrant or of any

                                       12
<PAGE>
rights granted  hereunder  contrary to the provisions of this Section 10, or the
levy of any attachment or similar process upon the Warrant or such rights, shall
be null and void.

     11. TAXES. The Company makes no  representation  about tax treatment to the
Holder with respect to receipt or exercise of the Warrant or acquiring,  holding
or disposing of the Warrant  Shares,  and the Holder  represents that the Holder
has had the  opportunity  to  discuss  such  treatment  with  the  Holder's  tax
advisers.

     12.  REMEDIES.  Each party stipulates that the remedies at law in the event
of any default or threatened  default by the other party in the  performance  or
compliance  with any of the terms of this Warrant may not be adequate,  and that
such  terms  may  be  specifically  enforced  by  a  decree  for  that  specific
performance  of any agreement  contained  herein or by an  injunction  against a
violation of any of the terms hereof or otherwise.

     13.  GOVERNING  LAW.  This  Warrant  shall be  construed  and  enforced  in
accordance with, and governed by, the laws of the State of Nevada without regard
to its principles of conflicts of laws.

     14. MISCELLANEOUS. This Warrant and any term hereof may be changed, waived,
discharged or terminated  only by an instrument in writing  signed by the Holder
and the Company.



               [THE REMAINDER OF THIS PAGE IS INTENTIONALLY BLANK]

                                       13
<PAGE>
ENOX BIOPHARMA, INC.

By: /s/ Itamar David
   ----------------------------------
Title: CFO

Address: 1687 West Broadway, Suite 303, Vancouver BC Canada

ACCEPTED AND AGREED:

[NITRICARE HB]


By: /s/ Jon Lundberg                       /s/ Eddie Weitzberg
   -------------------------------------   -------------------------------------
Title: Prof.                               Prof.

Address: Stenbocksvagen 6, S-182 62, Djursholm, Sweden


ACKNOWLEDGED:

DR. LUNDBERG JON


/s/ Jon Lundberg
-------------------------------------

DR. WEITZBERG EDDIE

/s/ Eddie Weitzberg
-------------------------------------


                                       14
<PAGE>
                                     ANNEX A

                               NOTICE OF EXERCISE

To: ENOX BIOPHARMA, INC.

The  undersigned  hereby  irrevocably  elects to purchase  ___________  ordinary
shares of Enox  Biopharma,  Inc.  issuable  upon the  exercise  of the  attached
Warrant and requests that a certificate for such shares be issued in the name of
the undersigned and delivered to the address stated below and, if such number of
shares  shall  not be all the  shares  that  may be  purchased  pursuant  to the
attached  Warrant,  that a new  Warrant  evidencing  the right to  purchase  the
balance of such shares be delivered  to the  undersigned  at the address  stated
below.

Payment enclosed in the amount of USD ________________.

Dated: ____________________________

[NITRICARE HB]

Address: __________________________

Signature: ________________________



                                       15